349 related articles for article (PubMed ID: 33299645)
1. The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics.
Shen X; Hu B; Xu J; Qin W; Fu Y; Wang S; Dong Q; Qin L
Cancer Biol Med; 2020 Nov; 17(4):937-952. PubMed ID: 33299645
[TBL] [Abstract][Full Text] [Related]
2. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
Huang X; Qiu Z; Li L; Chen B; Huang P
Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
[TBL] [Abstract][Full Text] [Related]
3. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
Jiang H; Ning G; Wang Y; Lv W
Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
[TBL] [Abstract][Full Text] [Related]
4. Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma.
Deng M; Fang L; Li SH; Zhao RC; Mei J; Zou JW; Wei W; Guo RP
Mutagenesis; 2021 Oct; 36(5):369-379. PubMed ID: 34467992
[TBL] [Abstract][Full Text] [Related]
5. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
[TBL] [Abstract][Full Text] [Related]
6. Identification of three m6A-related mRNAs signature and risk score for the prognostication of hepatocellular carcinoma.
Li Z; Li F; Peng Y; Fang J; Zhou J
Cancer Med; 2020 Mar; 9(5):1877-1889. PubMed ID: 31943856
[TBL] [Abstract][Full Text] [Related]
7. m6A regulator-mediated methylation modification highlights immune infiltration patterns for predicting risk in hepatocellular carcinoma.
Zhou D; Wang Y; Wei W; Zhou W; Gu J; Kong Y; Yang Q; Wu Y
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3661-3680. PubMed ID: 35972694
[TBL] [Abstract][Full Text] [Related]
8. RNA N6-Methyladenosine Patterns in Hepatocellular Carcinoma Reveal a Distinct Immune Infiltration Landscape and Clinical Significance.
Zhao H; Zhou Q; Shi C; Shao Y; Ni J; Lou J; Wei S
Med Sci Monit; 2021 Oct; 27():e930994. PubMed ID: 34690344
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive characterization of m6A methylation and its impact on prognosis, genome instability, and tumor microenvironment in hepatocellular carcinoma.
Yin T; Zhao L; Yao S
BMC Med Genomics; 2022 Mar; 15(1):53. PubMed ID: 35260168
[TBL] [Abstract][Full Text] [Related]
10. N6-methyladenosine (m6A) regulatory gene divides hepatocellular carcinoma into three subtypes.
Wei J; Fang DL; Zhou W; He YF
J Gastrointest Oncol; 2021 Aug; 12(4):1860-1872. PubMed ID: 34532134
[TBL] [Abstract][Full Text] [Related]
11. The significance of m6A RNA methylation regulators in predicting the prognosis and clinical course of HBV-related hepatocellular carcinoma.
Fang Q; Chen H
Mol Med; 2020 Jun; 26(1):60. PubMed ID: 32552682
[TBL] [Abstract][Full Text] [Related]
12. Analysis of m6A RNA Methylation-Related Genes in Liver Hepatocellular Carcinoma and Their Correlation with Survival.
Li Y; Qi D; Zhu B; Ye X
Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33540684
[TBL] [Abstract][Full Text] [Related]
13. m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma.
Du J; Ji H; Ma S; Jin J; Mi S; Hou K; Dong J; Wang F; Zhang C; Li Y; Hu S
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33594424
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
Chen YT; Xiang D; Zhao XY; Chu XY
Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
[TBL] [Abstract][Full Text] [Related]
15. m6A Modification Patterns With Distinct Immunity, Metabolism, and Stemness Characteristics in Soft Tissue Sarcoma.
Huang ZD; Lin LL; Liu ZZ; Hu C; Gu HY; Wei RX
Front Immunol; 2021; 12():765723. PubMed ID: 35003079
[TBL] [Abstract][Full Text] [Related]
16. m
Li W; Liu J; Ma Z; Zhai X; Cheng B; Zhao H
Dis Markers; 2021; 2021():8859590. PubMed ID: 34234878
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Analysis of N6-methyladenosine Modification Patterns Associated With Multiomic Characteristics of Bladder Cancer.
Liu J; Wang J; Wu M; Zhang W; Meng L; Wang J; Lv Z; Xia H; Zhang Y; Wang J
Front Med (Lausanne); 2021; 8():757432. PubMed ID: 35004726
[No Abstract] [Full Text] [Related]
18. Identification of METTL3 as an Adverse Prognostic Biomarker in Hepatocellular Carcinoma.
Liu GM; Zeng HD; Zhang CY; Xu JW
Dig Dis Sci; 2021 Apr; 66(4):1110-1126. PubMed ID: 32333311
[TBL] [Abstract][Full Text] [Related]
19. m
Wu Y; Li L; Wang L; Zhang S; Zeng Z; Lu J; Wang Z; Zhang Y; Zhang S; Li H; Chen T
BMC Cancer; 2024 Apr; 24(1):506. PubMed ID: 38649860
[TBL] [Abstract][Full Text] [Related]
20. HBXIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1α.
Yang N; Wang T; Li Q; Han F; Wang Z; Zhu R; Zhou J
J Cell Physiol; 2021 May; 236(5):3863-3880. PubMed ID: 33305825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]